RecruitingPhase 2NCT00977977
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Studying Glomerular disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Meryl A Waldman, M.D.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Intervention
- Rituximab Infusion(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-90 years · All sexes
- Timeline
- 2010 – 2027
Study locations (2)
- National Naval Medical Center, Bethesda, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00977977 on ClinicalTrials.govOther trials for Glomerular disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06858319Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Novartis Pharmaceuticals
- RECRUITINGPHASE4NCT05839314Effect of Huaier Granule on the Treatment of Idiopathic Membranous NephropathyChinese PLA General Hospital
- RECRUITINGNCT05505500Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.University of Michigan
- RECRUITINGNCT04528446The Impact of Glomerular Disorders on Bone Quality and StrengthColumbia University
- RECRUITINGNCT03929887KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisSeoul National University Hospital
- RECRUITINGNCT02954419IgA Nephropathy Biomarkers Evaluation Study (INTEREST)Sun Yat-sen University